Association of circulating monocyte chemoattractant protein‐1 levels with polycystic ovary syndrome: A meta‐analysis

Problem Polycystic ovary syndrome (PCOS) is a common hormonal disorder that has a huge impact on the human infertility. Increased levels of various circulating inflammatory cytokines have been observed in PCOS patients, which can contribute to the pathogenesis of PCOS. Monocyte chemoattractant protein‐1 (MCP‐1), a secretory chemokine, is a potent chemotactic factor that recruits monocytes/macrophages to inflammatory foci. Several previous studies comparing the circulating MCP‐1 levels between non‐PCOS and PCOS patients have yielded contradictory results. Therefore, the aim of this meta‐analysis was to investigate whether circulating MCP‐1 levels vary between non‐PCOS and PCOS patients. Methods Research articles published before November 11, 2020, were screened to identify eligible studies. Heterogeneity, sensitivity, and publication bias were analyzed using STATA software. Standardized mean difference (SMD) with a 95% confidence interval (CI) was calculated by the STATA software using a random‐effects model. Results 11 studies were included in this meta‐analysis involving 897 individuals: 368 non‐PCOS patient and 529 PCOS patients. Our pooled meta‐analysis results show that circulating MCP‐1 levels were significantly higher in PCOS patients than in non‐PCOS patients (SMD = 0.84, 95% CI = [0.37, 1.31], Z = 3.50, p